Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04522271

Resistant Starch in Pediatric Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis)

The purpose of the study is determine if a plant-based resistant starch that is optimized for the individual will target the underlying cause of inflammatory bowel disease and restore a "healthier" gut microbiome in pediatric participants with inflammatory bowel disease.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Crohn Disease Colitis Colitis, Ulcerative Colonic Diseases Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases Ulcerative Colitis

Age range

5 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Children's Hospital of Eastern Ontario

Ottawa, Ontario, K1H 8L1, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Capable of giving informed consent, or if appropriate, have an acceptable representative capable of giving consent on the participant's behalf.
  • Enrolled in the main parent study.
  • New ulcerative colitis diagnosis (mild/moderate) or Crohn's Disease diagnosis (moderate/severe) with colonic disease with or without terminal ileum disease, already started on oral corticosteroid or aminosalicylates for induction therapy at a time following diagnostic colonoscopy.
  • Clinically responsive to induction medical therapy at enrollment (Crohn's Disease participants with a weighted pediatric Crohn's Disease activity index decrease of ≥ 17.5 points or ulcerative colitis participants with a pediatric ulcerative colitis activity index decrease of ≥ 15 points).
  • Ability and willingness to comply with study procedures (e.g. stool collections) for the entire length of the study.
  • Willing to provide consent/assent for the collection of stool samples.

Exclusion criteria

  • Allergy to resistant starch or excipients.
  • Co-existing diagnosis with diabetes mellitus.
  • Treatment with another investigational drug or intervention throughout the study.
  • Current drug or alcohol dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Inability or unwillingness of an individual or legal guardian to give written informed consent.
  • Requirement for antibiotic therapy as part of standard Crohn's Disease therapy (i.e. those patients with penetrating disease as manifested by intra-abdominal abscess or perianal abscess).
  • Requirement of oral antibiotics for other conditions (e.g. acne).
  • Participant's microbiota does not produce butyrate in response to any of the assembled panel of resistant starch as measured through the Rapid Assay of an Individual's Microbiome (RapidAIM) evaluation following enrollment.
  • Requirement of therapy other than oral corticosteroid / aminosalicylates for induction therapy.
  • Patients diagnosed with Inflammatory Bowel Disease-Unclassified.
  • Refusal to undergo follow-up colonoscopy as part of current clinical practice guidelines for Crohn's Disease standard of care.

Treatment and study plan

Resistant starch

Other

7.5 g resistant starch/m2 oral consumption

Placebo

Other

Placebo oral consumption of food-grade cornstarch

Primary outcomes

  1. Increased potential for butyrate production and its level at the mucosal luminal interface following ingestion of an individualized resistant starch as assessed by meta-omics analysis.

    Time frame: 5 ± 1 months

  2. Sustained increased potential of butyrate production 6 months following cessation of the use of individualized resistant starch as assessed by meta-omics analysis of stools.

    Time frame: 12 ± 2 months

  3. The percentage of eligible inflammatory bowel disease (IBD) patients who will enter a resistant starch-based ingestion trial.

    Time frame: Enrollment

    Threshold of interest will be 50%.

  4. Compliance of resistant starch intake by patient report.

    Time frame: 5 ± 1 months

  5. Compliance of resistant starch intake by product reconciliation.

    Time frame: 5 ± 1 months

Secondary outcomes

  1. Change in microbiome composition of cases towards the microbiome of controls as assessed by meta-omics analysis.

    Time frame: 5 ± 1 months and 12 ± 2 months

  2. Changes in mitochondrial function due to ingestion of resistant starch as assessed by host proteomics of biopsy sampling.

    Time frame: Enrollment, and 5 ± 1 months

  3. Change in clinical disease activity as measured by the wPCDAI for Crohn's Disease, the PUCAI and Partial Mayo Score for Ulcerative Colitis, and the PGA for both Crohn's Disease and Ulcerative Colitis.

    Time frame: Enrollment, 5 ± 1 months, and 12 ± 2 months

    Weighted Pediatric Crohn's Disease Activity Index (wPCDAI) ranges from 0 to 125 points (<12.5 = remission, 12.5 to 40.0 = mild, >40.0 = moderate, >57.5 = severe). The Pediatric Ulcerative Colitis Activity Index (PUCAI) ranges from 0 to 85 points (<10 = remission, 10 to 34 = mild, 35 to 64= moderate, >65 = severe). Partial Mayo Score ranges from 0 to 9 points (0 to 1 = remission, 2 to 4 = mild, 5 to 6 = moderate, 7 to 9 = severe). The Physician Global Assessment (PGA) ranges from 0 to 3 points (0 = normal, 1 = mild, 2 = moderate, 3 = severe).

  4. Changes in patient reported disability outcomes as measured by the IBD Disability Index Questionnaire.

    Time frame: Enrollment, 5 ± 1 months, and 12 ± 2 months

    The IBD disability index consists of 28 questions and a higher overall score is indicative of greater disability.

  5. Changes in patient, parent/caregiver reported quality of life outcomes as measured by the IMPACT III Questionnaires.

    Time frame: Enrollment, 5 ± 1 months, and 12 ± 2 months

    The IMPACT III questionnaire (a health related quality of life questionnaire) consists of 35 questions and ranges in score from 0 to 231. A higher score represents a higher quality of life. The IMPACT III-P Questionnaire is to be completed by the caregiver/guardian with a higher score also representing a higher quality of life.

  6. Changes in intestinal mucosal inflammation by measuring fecal calprotectin through stool samples.

    Time frame: Enrollment, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 8 months, 10 months, and 12 months

  7. Change in endoscopic disease activity measured during colonoscopies using the SES-CD for Crohn's Disease and the Mayo Endoscopic Sub Score and UCEIS for Ulcerative Colitis.

    Time frame: Enrollment, and 5 ± 1 months

    The Simple Endoscopic Score for Crohn's Disease (SES-CD) measures disease inflammation (0 to 2= inactive, 3 to 6 = mild, 7 to 15 = moderate, >16 = severe). Mayo Endoscopic Sub Scores range from 0 to 3, with 0 representing a normal mucosa or inactive disease and 3 representing severe activity (spontaneous bleeding and large ulcerations). The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) ranges from 0 to 8 (0 to 1 = remission, 2 to 4 = mild, 5 to 6 = moderate, and 7 to 8 = severe).

  8. Change in histological scoring of acute and chronic inflammation collected through biopsies during colonoscopies and assessed using Naini and Cortina score for Crohn's disease and the Robarts Histopathological Index (RHI) for Ulcerative Colitis.

    Time frame: Enrollment, and 5 ± 1 months

    The Naini and Cortina score ranges from 0 to 10 for ileitis and 0 to 17 for colitis. For ileitis, the histopathological support for having IBD is either low (score < 2), moderate (score is 3 to 4), or high (score ≥ 5). For colitis, the likelihood of having IBD is either low (≤3), moderate (score is 4 to 8), or high (score ≥ 9). The Robarts Histopathological Index score ranges from 0 to 33 with a higher score representing more severe inflammation.

Sponsors and collaborators

Lead sponsor

Children's Hospital of Eastern Ontario

Other

Registry information

Official study title

A Single Center, Randomized, Placebo-controlled, Double-blinded, Parallel, Pilot Clinical Trial to Assess Plant-derived Food-based Resistant Starches Individually Optimized for Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)

Important dates

Study start
2020
Primary completion
2024
Study completion
2026
First posted
Aug 21, 2020
Registry last updated
Jan 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.